Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07858929

Application of the Maestro Surgical System for Surgical Assistance in Laparoscopic Abdominal Surgery

Application of the Maestro Surgical System for Surgical Assistance in Laparoscopic Abdominal Surgery — Recruiting • NCT07858929.

📅 05 Oct 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07858929
Start
2026-03-13
Completion
2027-03-12
ClinicaliQ Trial Snapshot
  • Application of the Maestro Surgical System for Surgical Assistance in Laparoscopic Abdominal Surgery — Recruiting • NCT07858929.
  • Study testing whether a robotic surgical system can safely assist surgeons during keyhole abdominal operations.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This study is designed to evaluate the application of the Maestro Robotic Platform for surgical assistance in laparoscopic abdominal surgery. The purpose of this study is to assess the system use in general surgery on different procedures, level of complexity, and type of setting (elective/emergency). Conditions: Abdominal Laparoscopic Surgery Interventions: Any abdominal laparoscopic surgery with the usage of the Maestro Platform. Lead Sponsor: Portsmouth Hospitals NHS Trust Planned Enrollment: 100 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn